CSL plans to spin off CSL Seqirus into a separately listed entity on the Australian Securities Exchange (ASX) by the end of the 2026 financial year. Seqirus, formed in 2015 through CSL’s acquisition of Novartis’ influenza vaccine business, reported revenues of $2.2 billion and an operating result of $1 billion in the 2025 fiscal year.
The demerger is expected to unlock significant value, with CSL projecting annual pre-tax cost savings of $500-550 million by 2028. Gordon Naylor, former president of CSL Seqirus, will chair the new company, positioning it as a leading global player in the $7 billion influenza vaccine market.
Workforce reductions and operational streamlining
The restructuring includes a reduction of up to 3,000 positions, excluding those in blood plasma collection centers. Additionally, CSL will close 22 underperforming plasma centers in the United States during the 2026 financial year. These measures are part of CSL’s strategy to simplify its operations and improve efficiency in response to competitive pressures and geopolitical uncertainties.
Financial outlook
Despite the restructuring, CSL reported a 14 percent increase in underlying net profit to $3.3 billion for the 2025 fiscal year. The company anticipates net profit for fiscal 2026 to be between $3.45 billion and $3.55 billion, representing a 7-10 percent increase over the previous year.To further enhance shareholder value, CSL announced a $750 million share buyback program and a final dividend of $1.62 per share, a 12 percent increase from the previous year.
